not receive an unlicensed investigational agent drug device or blood-derived product within 30 day prior to randomization and may not receive such an investigational agent in the 30 day post-randomization note investigational use for treatment of tma of a license immunomodulator e.g. rituximab be permit at any time relative to randomization 